Brief: Ventyx Biosciences Reports Q4 EPS USD -0.62
Mar 23 (Reuters) - Ventyx Biosciences Q4 operating expenses USD 38.571 million. * Q4 EPS USD -0.62 * Q4 net income USD -35.214 million
Recent news on Ventyx Biosciences
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (updated)
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026
Deals of the day-Mergers and acquisitions